Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells., PMID:23453631
CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival., PMID:23593209
Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells., PMID:23853580
Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors., PMID:24148617
PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads., PMID:24204962
CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA., PMID:24205056
[CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection]., PMID:25146744
CD160 isoforms and regulation of CD4 and CD8 T-cell responses., PMID:25179432
Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice., PMID:25327211
Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection., PMID:25449536
T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation., PMID:25769075
Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations., PMID:25965355
Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM., PMID:26202493
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis., PMID:27605882
Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier., PMID:27702550
Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection., PMID:27906829
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells., PMID:28588576
Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR., PMID:28654216
Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade., PMID:28882621
A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator., PMID:29061848
Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients., PMID:29245962
ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection., PMID:29541698
Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models., PMID:29860455
Ox40 regulates the conversion and suppressive function of double-negative regulatory T cells., PMID:30268799
[A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect]., PMID:30295284
Monocytes of Different Subsets in Complexes with Platelets in Patients with Myocardial Infarction., PMID:30300910
Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes., PMID:30770415
CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models., PMID:32363119
A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats., PMID:33154441
Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments., PMID:33382949
A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment., PMID:33539379
Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms., PMID:34250086
A novel 10-gene immune-related lncRNA signature model for the prognosis of colorectal cancer., PMID:34814366
Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity., PMID:34888843
Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy., PMID:34888847
Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren's Syndrome., PMID:35159987
Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection., PMID:35336991
Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma., PMID:35428910
Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing., PMID:35453072
Realigning the LIGHT signaling network to control dysregulated inflammation., PMID:35604387
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM., PMID:36081508
Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody-mediated rejection showing a new link between adaptive and innate humoral allo-immunity., PMID:37220805
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors., PMID:37230538
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056
Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy., PMID:37649037
Linking donor-specific antibody generation with natural killer cells in antibody-mediated kidney graft rejection., PMID:37739612
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer., PMID:38290769
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications., PMID:38360636
Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV., PMID:38728839
For research use only. Not for human or drug use.
